|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.10 / 0.19|
The biotech's shares sink more than 13% after the company drops its bid to find a buyer.
U.S. stocks hold up well after British authorities say they foil a plot to destroy commercial jets.
The drugmaker tops estimates for the second quarter, but a criminal inquiry weighs on the shares.
Earnings were solid, but cheaper biotechs can be found, including another name that just reported.
The company has been forsaken in its merger bid, and little suggests that will change.
The VIX holds its ground, and the put/call ratio closes above 1 for the fifth time in the last seven sessions.
The markets are likely to struggle again next week as Middle Eastern violence only intensifies.
The drugmaker certainly doesn't have overwhelming support on Wall Street, but a Plavix deal helps.
The $250 million payment from Bristol-Myers will be the last one under their agreement.
Don't mess with Starbucks, or the U.S. Congress when it's trying to protect oil industry profits. Plus, much more corporate hilarity!
The ImClone drug and radiation extended patient lives for longer than radiation alone.
The drug giant says in an SEC filing that it has no plan to acquire the Erbitux maker.
Adjusted EPS of 31 cents in the fourth quarter beats estimates.
A cooling economy may stoke M&A as firms facing slowing sales aim to employ cash.
The company sets up a $185 million reserve to cover an anticipated litigation settlement.
Immucor bleeds after its third-quarter results fall short and the company slashes its outlook.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.